Bulletin
Investor Alert

press release

Aug. 30, 2021, 4:06 p.m. EDT

Olema Oncology to Present at Morgan Stanley 19th Annual Global Healthcare Conference

SAN FRANCISCO, Aug 30, 2021 (GLOBE NEWSWIRE via COMTEX) -- SAN FRANCISCO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology," Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19 [th] Annual Global Healthcare Conference on Monday, September 13, 2021, at 4:15 p.m. ET (1:15 p.m. PT).

A live webcast of the presentation may be accessed under the Investors & Media section of Olema's website ( www.olema.com ) and will be archived for 14 days.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers. Olema's lead product candidate, OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

Contact:
Eva Stroynowski
Vice President, Communications and Investor Relations
eva@olema.com

COMTEX_392452346/2471/2021-08-30T16:05:55

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

Partner Center

Link to MarketWatch's Slice.